However, it is currently unclear if ATRX mutations and/or the immunogenic phenotype are associated with sensitivity to immunotherapies commonly used in children with neuroblastoma including anti-GD2 antibody, which is currently given as standard of care. Here, ATRX is linked to neuroblastoma.